Compositions and methods for immunooncology
US-2024417722-A1 · Dec 19, 2024 · US
N-glycosylation
US10858671B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10858671-B2 |
| Application number | US-201515534735-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 11, 2015 |
| Priority date | Dec 12, 2014 |
| Publication date | Dec 8, 2020 |
| Grant date | Dec 8, 2020 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to a mammalian cell comprising a gene encoding a polypeptide of interest, wherein the polypeptide of interest is expressed comprising one or more posttranslational modification patterns. These modifications are useful for example in glycoprotein production where the antibodies with the modifications have an enhanced antibody-dependent cell-mediated cytotoxicity (ADCC). The present invention also relates to methods for producing the glycoproteins and compositions comprising the glycoproteins, and their uses.
First claim
Opening claim text (preview).
The invention claimed is: 1. An isolated mammalian cell comprising homogeneous biantennary N-glycans, wherein mgat4A, mgat4B, and mgat5 are inactivated in the cell, thereby generating the homogeneous biantennary N-glycans in the cell. 2. The cell according to claim 1 , wherein the genes are inactivated using zinc finger nucleases, TALENs, or CRISPR/Cas9. 3. The cell according to claim 1 , wherein mgat4C is additionally inactivated. 4. The cell according to claim 1 , wherein mgat5B is additionally inactivated. 5. The cell according to claim 1 , wherein FUT8 is additionally inactivated. 6. The cell according to claim 1 , wherein B3gnt2 is additionally inactivated. 7. The cell according to claim 1 , wherein mgat2 is additionally inactivated. 8. The cell according to claim 1 , wherein ST3gal3, ST3gal4, and ST3gal6 are additionally inactivated. 9. The cell according to claim 1 , wherein ST6Gal1 is knocked in. 10. The cell according to claim 1 , wherein the cell is a CHO, NSO, SP2/0, YB2/0, CHO-K1, CHO-DXB11, CHO-DG44, CHO-S, HEK293, HUVEC, HKB, or PER-C6 cell. 11. The cell according to claim 10 , wherein the cell is a CHO cell. 12. The cell according to claim 1 , further comprising EPO, an IgG antibody, a protein involved in hemostasis, or a coagulation factor.
Assignees
Inventors
Classifications
Glycosyltransferases (EC 2.4.) · CPC title
containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered · CPC title
Erythropoietin [EPO] · CPC title
variable (Fv) region, i.e. VH and/or VL · CPC title
Glycopeptides, glycoproteins · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10858671B2 cover?
- The present invention relates to a mammalian cell comprising a gene encoding a polypeptide of interest, wherein the polypeptide of interest is expressed comprising one or more posttranslational modification patterns. These modifications are useful for example in glycoprotein production where the antibodies with the modifications have an enhanced antibody-dependent cell-mediated cytotoxicity (AD…
- Who is the assignee on this patent?
- Univ Copenhagen, Univ Danmarks Tekniske, Dansmarks Tekniske Univ
- What technology area does this patent fall under?
- Primary CPC classification C12N15/907. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Dec 08 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).